Chapel Disease Therapeutics Market Size is valued at USD 144.89 Mn in 2023 and is predicted to reach USD 161.10 Mn by the year 2031 at a 1.41% CAGR during the forecast period for 2024-2031.
Chapel Syndrome is a rare genetic condition affecting the immune system. CHAPLE stands for "CD55 deficiency, hyperactivation, angiopathic thrombosis, and severe protein-losing enteropathy (PLE)." Chaple is characterized by severe protein-losing enteropathy, which can result in hypoproteinemia. Chronic malabsorption is a condition that causes nutrient shortages, including iron, ferritin, and calcium. Patients with significant thrombotic or vascular blockages may also be impacted. CHAPLE syndrome is caused by mutations in the complement regulator gene, which cause a decrease in protein expression.
The Chaple syndrome is primarily inherited as autosomal recessive. This indicates that a child normally inherits one copy of each parent's defective gene, resulting in a homozygous deficiency. Chaple syndrome patients can be diagnosed using a combination of clinical symptoms, genetic testing, and histology. The histopathological examination of intestinal biopsy specimens (or resections) revealed significant lymphangiectasia. This points to a diagnosis of primary intestinal lymphangiectasia. Large-vein thrombosis is also possible in patients. The patient's clinical status determines the treatment plan. Kurolap and his colleagues gave patients off-label eculizumab. This is a humanized monoclonal anti-C5 antibody and complement inhibitor. The treatment was effective for 18 months. The chapel syndrome is a market with an increasing number of patients.
Increased demand for iron supplements, Eculizumab, a blood thinner, and bone marrow transplants for genetically predisposed patients is driving market expansion. Market growth is also affected by pharmaceutical companies' expanded research and development operations to provide additional treatment facilities, as well as an increase in demand for therapies to treat the condition. Research and development, as well as increased research funding, benefit the chapel syndrome market. CHAPLE syndrome is distinguished by complement-mediated autoimmune hemolysis and nocturnal hemoglobinuria. The decay-accelerating element, commonly known as CD55, plays a role in regulating the complement cascade. If CD55 is not present, the complement system targets and destroys blood cells (hemolysis). CD55 deficiency is associated with hyperactivation, angiopathic thrombosis, and CD55 (the CHAPLE Syndrome). Surprisingly, deletion of CD55, a crucial regulator of the complement system, results in a mainly gastrointestinal disease.
Competitive Landscape
Some Major Key Players In The Chapel Disease Therapeutics Market:
- Alexion Pharmaceuticals Inc.
- Akari Therapeutics
- Apellis Pharmaceuticals
- Amgen Inc.
- CinnaGen Co.
- Novartis AG
- Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals Inc.
- Alnylam Pharmaceuticals, Inc.
- Other Prominent Players
Market Segmentation:
The Chaple Disease Therapeutics Market is segmented by type, diagnosis, and distribution channel. Based on type, the market is segmented into Eculizumab, Ravulizumab, and Veopoz. By diagnosis, the market is segmented into Gastrointestinal Symptoms, Edema, Hypoalbuminemia, Hypogammaglobulinemia, and Malnutrition. As per the distribution channel, the market is categorised into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.
Based On Type, Eculizumab And Ravulizumab Are Key Players In The Chapel Disease Market.
Eculizumab and Ravulizumab are key players in the Chapel Disease market. Both are significant drugs for the treatment of Chapel Syndrome. They are classed as complement inhibitors and work by addressing the disease's underlying cause, a deficit in the complement factor H protein. These drugs have been found to help people with Chapel Syndrome manage their symptoms and improve their quality of life. Veopoz, on the other hand, has no unique association with Chapel Syndrome.
Gastrointestinal Problems Are A Significant Market Niche.
Gastrointestinal symptoms are a popular area of the Chapel Disease market. Chapel Syndrome is defined by a variety of gastrointestinal symptoms, including chronic diarrhea, abdominal pain, and malabsorption. These symptoms substantially influence the quality of life for people with Chapel Syndrome and are frequently addressed in treatment and management measures. Addressing gastrointestinal symptoms is critical to increasing overall well-being and decreasing Chapel Syndrome's influence on everyday living.
In The Region, The North America Chaple Disease Therapeutics Market Holds Significant Revenue Share.
North America is predicted to be the most important market for chaple disease therapies throughout the forecast period. The North American area dominates the worldwide chaple disease treatments market due to the existence of numerous leading pharmaceutical companies and high healthcare expenditure. In addition, the Asia Pacific market is predicted to be the fastest-growing for chaple disease therapies, accounting for more than 20% of the market throughout the projection period. The market in Asia Pacific is expanding very fast as a result of positive legislative backing, infrastructure upgrades, and changing customer preferences.
Recent Developments:
- In Aug 2023, The FDA granted approval for Regeneron's pozelimab as the first medication for patients with the extremely rare disease CHAPLE. This treatment is authorized for anyone aged one and older who inherited this disorder.
- In June 2023, Amgen successfully finalized its purchase of Horizon Therapeutics plc for $116.50 per share in cash, resulting in a total transaction equity value of almost $27.8 billion.
Chapel Disease Therapeutics Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 144.89 Mn |
|
Revenue Forecast In 2031 |
USD 161.10 Mn |
|
Growth Rate CAGR |
CAGR of 1.41% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Diagnosis, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Alexion Pharmaceuticals Inc., Akari Therapeutics, Apellis Pharmaceuticals, Amgen Inc., CinnaGen Co., Novartis AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., and Alnylam Pharmaceuticals, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
